Regeneron Pharmaceuticals Inc Says Dupixent® (Dupilumab) To Treat Chronic Spontaneous Urticaria (Csu) Advances In EU With Positive CHMP Opinion
Sept 22 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON PHARMACEUTICALS INC - DUPIXENT® (DUPILUMAB) TO TREAT CHRONIC SPONTANEOUS URTICARIA (CSU) ADVANCES IN EU WITH POSITIVE CHMP OPINION
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

Tradingkey







